Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23884038.
- Also identified by DOI 10.1212/WNL.0b013e3182a2cc4a and PMC identifier 3908464.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,(1-4) but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS).
Medical subject headings
- Adjuvants, Immunologic
- Chemical and Drug Induced Liver Injury
- Multiple Sclerosis, Relapsing-Remitting
- Peptides